575 / 1631
Conclusions
•
Outcomes are improving in patients with indolent NHL.
•
Immunochemotherapy combinations have been extremely effective, but
likely have reached a “plateau” and for majority of patients have life
expectancy similar to aged matched control.
•
Different approaches are required for POD-24 – early consideration of
transplantation approaches and novel agents
•
Novel non-cytotoxic drugs as single agents are active in iNHL.
•
Next generation regimens combine biological and targeted agents.
•
Mechanistic and biomarker studies are still lacking in the majority of
studies, but are essential to optimize therapy.